Reuters·2026-02-03 05:29Core Viewpoint - ResMed, a maker of sleep-breathing devices, is launching a global doctor education program to promote the screening of patients seeking Ozempic-style weight loss drugs for sleep apnea [1] Group 1: Company Initiatives - ResMed plans to implement a global education program aimed at doctors to enhance awareness and screening for sleep apnea among patients using GLP-1 receptor agonists like Ozempic [1] - The initiative reflects ResMed's commitment to addressing the intersection of weight loss treatments and sleep health [1] Group 2: Industry Context - The rise in popularity of Ozempic and similar weight loss drugs has prompted a need for increased screening for sleep apnea, as these medications can impact respiratory health [1] - The program aims to educate healthcare providers on the importance of screening for sleep apnea in patients who are prescribed these weight loss medications [1]